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S U M M A R Y
Objectives: To assess differences between injecting drug users (IDUs) with hepatitis C virus (HCV)
viremia and IDUs with HCV antibody (Ab) or no evidence of prior infection in three Afghan cities.
Methods: IDUs in Hirat, Jalalabad, and Mazar-i-Sharif completed questionnaires and rapid testing for
blood-borne infections including HCV Ab. HCV Abwas conﬁrmedwith a recombinant immunoblot assay
(RIBA); RIBA-positive specimens underwent reverse transcriptase polymerase chain reaction (RT-PCR)
for HCV. Risk behaviors associated with viremia were assessed with site-controlled ordinal regression
analysis.
Results: Of 609 participants, 223 (36.6%) had conﬁrmed HCV Ab. Of 221 with serum available for PCR
evaluation, 127 (57.5%) were viremic. HCV viremia prevalence did not differ by site (range 41.7–59.1%;
p = 0.52). Among all IDUs, in age and site-controlled ordinal regression analysis, HCV was independently
associated with HIV co-infection (adjusted odds ratio (AOR) 7.16, 95% conﬁdence interval (CI) 4.41–
11.64), prior addiction treatment (AOR 1.95, 95% CI 1.57–2.42), ever aspirating and re-injecting blood
(AOR 1.62, 95% CI 1.18–2.23), prior incarceration (AOR 1.60, 95% CI 1.04–2.45), and sharing injecting
equipment in the last 6 months (AOR 1.35, 95% CI 1.02–1.80).
Conclusion: HCV viremia was present in many participants with prior HCV infection and was associated
with some injecting risk behaviors, indicating a substantial risk for transmission. Current harm reduction
programs should aim to improve HCV awareness and prevention among IDUs in Afghanistan as a matter
of urgency.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Hepatitis C virus (HCV) is a serious health threat for injecting
drug users (IDUs), among whom risky practices such as sharing
syringes, other injecting equipment, or drug preparations may
transmit infection.1 HCV-associated morbidity among IDUs may
manifest as hepatic failure and cirrhosis from chronic infection;
this process may be accelerated and ampliﬁed by co-infection with
HIV or hepatitis B virus (HBV).1 Acute HCV is symptomatic in 10–
15% of cases; those who are asymptomatic in the acute phase of§ Presented in part as a poster entitled ‘‘Prevalence of HIV, viral hepatitis, syphilis
and risk behaviors among injection drug users in Hirat, Afghanistan’’ (MOPE-0280),
at the International AIDS Conference, Mexico City, Mexico, August 5, 2008.
* Corresponding author. Tel.: +1 212 305 4805; fax: +1 212 305 6438.
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doi:10.1016/j.ijid.2010.11.006infection are more likely (85–95% vs. 48–75%) to progress to
chronic infection.2
Injecting drug use is a primary mode of transmission for HCV in
developed countries. In developing countries, HCV transmission
more commonly results from transfusion and unsafe medical
practices.1,2 However, HCV among IDUs in developing countries
has been acknowledged as a burgeoning health issue, particularly
in settings where HCV transmission is considered a harbinger of
HIV epidemics among this population.3–5 High HCV prevalence has
been recorded among IDUs in many Asian settings, including
Pakistan, India, and Iran, several of which are also highHCV burden
countries (general population prevalence >2.9%).1,6–9 The HCV
prevalence found among IDUs in two urban settings in Afghanistan
has been shown to range from36.6% to 49.1% andmay increase due
to the risk of both injection-related and other potential expo-
sures.10,11 Increasing numbers of IDUs in Afghanistan and the
common practice of sharing needles, syringes, injecting equipmentses. Published by Elsevier Ltd. All rights reserved.
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‘playing with blood’) may also contribute to an increasing
prevalence of HCV among Afghan IDUs.10,12
Longitudinal studies have indicated that some IDUs previously
infected with HCV are able to clear subsequent infections; this
association persisted after adjustment for risky behaviors.13,14
However, the risky behaviors that increase the likelihood of re-
infection also increase the likelihood of HCV transmission to other
IDUs due to the presence of viremia in re-infected individuals. IDUs
with measurable viremia may differ signiﬁcantly with respect to
risky behaviors from those with either evidence of past infection or
no evidence of prior infection, and are of special interest due to their
ability to transmit infection to others. IDUs with viremia may also
differ by biological factors; however, it is important to assess the
relative association of behavioral factors, as thesemay be addressed
throughprevention programs. Our previous cross-sectional study in
Kabul was conducted prior to the availability of nucleic acid testing
in Afghanistan, so no information could be obtained regarding
prevalence and traits associatedwith viremia. The data presented in
this manuscript result from the follow-on assessment conducted
between 2006 and 2008 in three other Afghan urban centers.
Recent data from a longitudinal study among IDUs in Kabul
revealed high HCV incidence in a setting with many new
injectors.15 Assessment of whether IDUs with detectable viremia
are distinct from thosewith antibody alonemay provide important
information to prevention programs in other Afghan cities to avert
the HCV epidemic currently underway in Kabul. The purpose of
this analysis was to determinewhether the sub-group of IDUswith
HCV viremia differs signiﬁcantly from IDUswith either no evidence
of prior infection or HCV antibody (HCV Ab), and to determine
whether behaviors associated with HCV infection are more likely
among IDUs with HCV viremia in three Afghan cities.
2. Methods
2.1. Setting
This study was conducted among IDUs in Hirat, Mazar-i-Sharif,
and Jalalabad, the largest cities in their respective regions of
Afghanistan. At the time of this study, private and public
detoxiﬁcation programs were operating in all cities; there was
one harm reduction program operating in the city of Hirat with on-
site needle exchange. The other two cities did not have functioning
needle and syringe programs (NSPs) and no city had programs
offering either opioid substitution therapy or the hepatitis B
vaccine to IDUs at the time of the study.
2.2. Study design and participants
This cross-sectional study enrolled participants between
September 2006 and January 2008 through the Ministry of Public
Health-afﬁliated Voluntary Counseling and Testing centers (VCT),
public and private harm reduction outreach programs (a few of
which had VCT services on offer within their organizations), and
the International Rescue Committee (IRC) ofﬁces in each location.
Eligible participants were those reporting injecting drugs (con-
ﬁrmed through physical evidence of recent injection) within the
past 6 months, aged 18 years or older, and who were able to
provide written informed consent. Participants answered a series
of questions to ensure comprehension of the study risks and
beneﬁts and the requirements of participation; participants unable
to sign their name provided a ﬁngerprint. Approval was obtained
from the institutional review boards of the University of California,
San Diego, the Walter Reed Army Institute of Research, the US
Naval Medical Research Unit 3 in Cairo, Egypt, and the Ministry of
Public Health of the Islamic Republic of Afghanistan.2.3. Measurement of variables and outcomes of interest
The outcomes of interest for this analysis were the determina-
tion of whether IDUs with HCV viremia differ signiﬁcantly from
those with prior HCV infection and whether the association
between HCV infection and various risky behaviors strengthens in
a continuum from seronegative to viremic status. The question-
naire instrument assessed sociodemographic factors, travel,
incarceration and medical histories, and drug use and sexual
behaviors. Drug use behaviors of interest included sharing needles/
syringes ever and in the last 6 months, sharing injecting ‘works’
(e.g., cookers, cotton) ever and in the last 6 months, duration of
injecting, injecting while incarcerated, and aspirating and re-
injecting blood. Iatrogenic routes of blood-borne infection
transmission were also assessed, such as the receipt of therapeutic
injections from both medical and non-medical providers and both
the provision and receipt of transfused blood.
2.4. Procedures
Potential participants were recruited by experienced out-
reach workers afﬁliated with local harm reduction programs in
each city. Trained study staff obtained informed consent,
administered the study questionnaire, and performed rapid
testing and counseling in a private setting. Laboratory methods
for other pathogens have been reported in a related publica-
tion.16 Brieﬂy, whole blood rapid testing for HCV Ab was
performed using Standard Diagnostics HCV Ab (Standard
Diagnostics, Kyonggi-do, Korea). The manufacturer reports
100% sensitivity and 94.1% speciﬁcity by World Health
Organization (WHO) evaluation.17 Serum specimens were
obtained from participants with positive rapid tests; HCV Ab
was conﬁrmed with a recombinant immunoblot assay (RIBA 3.0
SIA1, Chiron Corp., Emeryville, CA, USA). The presence of HCV
was assessed with a qualitative reverse transcriptase polymer-
ase chain reaction (RT-PCR). Extraction was performed using the
QiAamp Viral RNA Mini Kit (Qiagen Inc., Germantown, MD, USA)
according to the manufacturer’s instructions. A nested RT-PCR
was performed as previously described, with minor modiﬁca-
tions of cycle parameters and master mix components.18 Both
RIBA and PCR were performed at the Afghan Public Health
Institute laboratory in Kabul, with the exception of HBV PCR,
which was performed at the United States Naval Medical
Research Unit 3 (NAMRU-3) laboratory in Cairo, Egypt.
Conﬁrmatory results were available after 2 weeks; participants
were provided with follow-up appointments at the time of
enrollment. All participants received post-test counseling, risk
reduction counseling, a small non-monetary gift of hygiene items
(e.g., razor, soap) of US$4 value, condoms, and sterile syringes, with
referrals for detoxiﬁcation programs upon request. No data were
recorded on those declining or ineligible for study entry.
Enrollment was conducted for 12 months at all sites.
2.5. Statistical analysis
Descriptive statistics for viremic individuals were generated,
with site differences assessed using the Chi-square test. Risky
behaviors, such as sharing syringes and injecting works, were
reported by frequency; these variables were dichotomized into
ever/never in the last 6 months.
Univariate logistic regression was performed to identify
potential associations between HCV viremia and select demo-
graphic, biological, and individual risk behavior variables, con-
trolled by enrollment site, of all conﬁrmed HCV Ab-positive
participants. Variables were entered into a site- and age-adjusted
multivariable model if they were associated with HCV viremia at
Table 1
Demographic and behavioral characteristics of male injecting drug users with HCV viremia in three Afghan cities (n=127)
Feature Hirat Jalalabad Mazar-i-Sharif p-Value
HCV viremia; % of HCV Ab-pos IDUs who were viremic/site (n=221) 58.2% (96) 41.7% (5) 59.1% (26) 0.520
Age, years, mean (SD) 30.2 (7.3) 27.2 (6.3) 31.5 (9.1) 0.006
Age initiated injecting, years, mean (SD) 27.3 (7.0) 24.2 (4.3) 26.2 (7.9) 0.736
Civil status: ever married, % (n) 46.9% (45) 80% (4) 42.3% (11) 0.299
Education: 6 years, % (n) 35.4% (34) 60% (3) 30.8% (8) 0.457
Lived/worked outside Afghanistan in last decade, % (n) 95.8% (92) 60% (3) 76.9% (20) <0.001
Ever in jail: Yes, % (n) 76.8% (73)b 40% (2) 73.1% (19) 0.177
Injected in jail:a Yes, % (n) 16.9% (12)c 0 (0) 21.1% (4) 0.767
Shared syringes in last 6 months: Yes, % (n) 26.1% (24)d 80% (4) 19.2% (5) 0.018
Shared injecting works last 6 months: Yes, % (n) 38.5% (37) 0 (0) 19.2% (5) 0.049
Aspirating and re-injecting blood: Yes, % (n) 78.1% (75) 80% (4) 92.3% (24) 0.261
Prior addiction treatment: Yes, % (n) 76.0% (73) 40% (2) 26.9% (7) <0.001
HCV, hepatitis C virus; Ab, antibody; pos, positive; IDU, injecting drug user; SD, standard deviation.
a Denominator is number ever having been incarcerated/site.
b Of 95 respondents.
c Of 71 respondents.
d Of 92 respondents.
Table 2
Factors independently associated with HCV viremia among HCV antibody-positive
injection drug users in three Afghan cities, controlling for site and age (n=221)
Variable AOR (95% CI)
HIV co-infection 1.47 (1.29–1.66)
HBV co-infection 0.48 (0.43–0.51)
Share syringes in last 6 months 0.40 (0.29–0.55)
HCV, hepatitis C virus; HIV, human immunodeﬁciency virus; HBV, hepatitis B virus;
AOR, adjusted odds ratio; CI, conﬁdence interval.
Table 3
Variables independently associated with HCV viremia among male injecting drug
users in three cities of Afghanistan in ordinal logistic regression, controlled for age
and site (N=609)
Variable AOR (95% CI)
HIV co-infection 7.16 (4.41–11.64)
Prior addiction treatment 1.95 (1.57–2.42)
Ever aspirate and re-inject blood 1.62 (1.18–2.23)
Ever been incarcerated 1.60 (1.04–2.45)
Shared injecting equipment last 6 months 1.35 (1.02–1.80)
Ever received injection from non-medical provider 0.30 (0.10–0.89)
HCV, hepatitis C virus; HIV, human immunodeﬁciency virus; AOR, adjusted odds
ratio; CI, conﬁdence interval.
A. Nasir et al. / International Journal of Infectious Diseases 15 (2011) e201–e205 e203the 10% level in univariate analysis or were considered of
epidemiological signiﬁcance.
Ordinal logistic regression was performed to identify associa-
tions between various HCV infection states and select demograph-
ic and risk behavior variables, adjusting for site and age. The
reference group was deﬁned as participants with no evidence of
prior HCV infection (antibody-negative by rapid test or by RIBA),
assigned the value of 0, with conﬁrmed HCV Ab-positive
participants assigned the value of 1 and those with HCV Ab and
detectable viremia assigned the value of 2. A multivariable model
was generated to identify factors independently associated with
HCV infection states using the Wald test to determine which
variables were retained at p < 0.05. The proportional odds
assumption of ordinal regression was tested using the Brant test.
3. Results
Of 623 IDUs recruited in the three Afghan cities (Hirat n = 340,
Jalalabad n = 96, and Mazar-i-Sharif n = 187), eight female IDUs
were excluded as the low number of female participants precluded
accurate description and adjustment by sex. As stated in the
Methods, only participants with conﬁrmed HCV Ab by RIBA were
included in the subsequent analyses. Of 615 total male partici-
pants, 609 had HCV rapid testing performed. Of 229 participants
with reactive HCV rapid tests with serum available for RIBA, 223
were RIBA-reactive, two were RIBA-indeterminate, and four were
negative (positive predictive value 97.4%). Two of the 223 male
IDUs with reactive RIBA tests did not have sufﬁcient serum
available for PCR testing and were excluded, leaving 221 for the
analysis.
The overall prevalence of RIBA-conﬁrmed HCV Ab was 36.6%
(n = 223/609), with signiﬁcant variance by site (p < 0.001). Of 221
participantswith HCV Ab and sufﬁcient available specimen for PCR
testing, 127 (57.5%) had detectable viremia. There was no
signiﬁcant difference in prevalence of viremia among IDUs with
positive HCV Ab by site, with 41.7% in Jalalabad, 59.1% in Mazar-i-
Sharif, and 58.2% in Hirat. However, there were signiﬁcant site
differences among viremic individuals by age, sharing syringes/
needles or injecting paraphernalia, having lived outside the
country in the last 10 years, and having previous addiction
treatment (Table 1). Further, age alone was positively associated
with viremia (odds ratio (OR) 1.04, 95% conﬁdence interval (CI)
1.00–1.08). Due to these differences by site and age, all further
analyses were controlled for these factors. All detected HIV cases
were positive for HCV Ab and were enrolled in Hirat. Reported
therapeutic injections in the last 6 months (13.4%, n = 17),therapeutic injections by a non-medical provider (3.1%, n = 4),
and blood donation (7.1%, n = 9) or transfusion at any time (4.7%,
n = 6) were rare among viremic IDUs.
Injecting behaviors and other risk markers were compared
between IDUs with HCV viremia and those with HCV Ab only
(Table 2). HIV co-infection was positively independently associat-
ed with HCV viremia, but HBV co-infection and sharing syringes or
needles in the last 6monthswere negatively associated in age- and
site-controlled multivariable regression.
In age- and site-controlled ordinal logistic regression analysis,
the spectrum (range 0–2) of HCV disease from antibody to viremia
was independently associated with HIV co-infection, prior
incarceration, sharing injecting equipment in the last 6 months,
khoon bozee, and prior addiction treatment, while a negative
association between HCV infection and ever receiving therapeutic
injection from a non-medical provider persisted (Table 3).
4. Discussion
Circulating viruswas present in at least 40% of participantswith
HCV Ab and did not vary signiﬁcantly by site, ensuring a
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inclusive of these IDUs. We acknowledge that this ﬁgure likely
underestimates viremia, as sustained viremia without detectable
antibody levels has been noted among IDUs in longitudinal studies
in the Netherlands and the USA.19–21 Though not statistically
signiﬁcant, IDUs in Jalalabad were less likely to have detectable
viremia. One possible reason for this observationmay be the social
organization of injectors in Jalalabad, where many participants
lived outside the city center, had initiated injecting in small
networks afﬁliated with the opium processing industry, and only
came to the city for addiction treatment or trade reasons (personal
communication, Dr M. Nasiry, assistant study manager, Jalalabad).
In comparisons between viremic IDUs and IDUs with HCV Ab
alone, the odds of viremia increased with age. Viremia was less
likely for older IDUs on opioid replacement therapy in Australia,
suggesting that the observed association in Afghanistan may be
behavioral rather than physiological.22 One hypothesis for this
observation may be that injecting networks tend to consist of
individuals of similar age, seen as peers. HIV co-infection was
positively associated with HCV viremia, similar to ﬁndings among
IDUs in several urban centers in the USA.23,24 Grebely et al., in a
longitudinal study, found that IDUs with HIV co-infection have
higher rates of HCV clearance; however, incident HCV re-infection
was twice as high among HIV-infected individuals.14 The clearance
rate among those with HCV re-infection was 29% (4/14); none of
the six HIV-infected participants re-infected with HCV cleared
their viremia.14 Sharing needles/syringes in the last 6 months was
negatively associated with viremia, which is surprising as this
group would likely be at greater risk for recent infection or re-
infection, as noted among the Canadian cohort.14 The negative
association between detectable viremia and HBV viremia may be
explained by the observed higher HCV clearance rates in the
presence of chronic HBV infection, similar to ﬁndings among
hemophiliac and female patient populations.25,26
Several behaviors or conditions were progressively more
associated with the presence of both viremia and HCV Ab. The
strongest association was between HIV co-infection and HCV,
likely reﬂective of both infections resulting from some of the same
risky behaviors, as noted in China, Iran, and India.6,27,28 Prior
incarceration was associated with increasing odds of HCV,
potentially reﬂecting sharing of injecting equipment and mixing
of injecting networks in prison settings, previously detected in a
variety of settings.6,29,30 Similarly, previous addiction treatment
may reﬂect mixing of injecting networks during or following the
course of treatment, as participants in this study reﬂect active IDUs
who have relapsed.
Sharing injecting ‘works’ (e.g., cookers, cotton) in the last 6
months was associated with the HCV spectrum but not with HCV
viremia among those with HCV infection. This association was
unexpected, as recent risk behaviors would seemmore likely to be
linked to viremia present in recent infection/re-infection.31,32 We
did not assess whether ever sharing works was associated with
HCV viremia, as recent behaviors were deemed more relevant.
Sharing of needles and syringes and potentially injecting works
may be under-reported ormay have ceased due to thesemessages.
Participants enrolled in Hirat, most of whom had been refugees in
Iran and were exposed to harm reduction messaging in that
setting, had a higher prevalence of HCV Ab. Though analyses were
controlled for site, under-reporting in Hirat of sharing, a
stigmatized behavior, may have inﬂuenced results. Aspirating
and re-injecting blood was independently associated with chronic
HCV infection andmay serve as a proxy for risky sharing behaviors,
as hypothesized for IDUs in Pakistan.9
Receipt of a therapeutic injection from a non-medical provider
was positively associated with the presence of HCV antibody
among IDUs in Kabul, which was the rationale for including thisvariable in our analysis.10 This variable was negatively associated
with HCV in our ordinal analysis and, though this relationship was
statistically signiﬁcant, therewere relatively few individuals in any
group reporting prior injections from non-medical providers. We
believe these low numbers indicate a spurious relationship. Of
note, reported receipt of a therapeutic injection ever or in the last 6
months was similarly rare. Other potential markers of iatrogenic
transmission will be considered in future studies.
Due to cost limitations, we did not obtain serum samples or
perform PCR for participants with negative HCV Ab rapid tests.
Therefore, we are unable to comment on circulating virus among
participants with HCV infection without detectable antibody, such
as those with acute (<12 weeks) infection, immune compromise,
or delayed/absent humoral response.2,19 Further, the number of
participants with viremia may have been further underestimated
based on the threshold for detecting virus with the qualitative PCR
assay used. This assay may not have been sensitive enough to
detect those participants who were chronically infected but had
low circulating viral levels.19 The rapid tests used cite a sensitivity
of 100%, indicating that true positives were unlikely to have been
missed in the initial screening.17 However, though the manufac-
turer’s fact sheet states the evaluationwas performed by theWHO,
no WHO source could be identiﬁed to conﬁrm the ﬁndings. The
performance characteristics of the rapid test may also have been
affected by setting. Additionally, risky injecting practices were
based on self-report and may have been under-reported. We did
not map injecting networks and so cannot comment on risk
behaviors within speciﬁc networks as related to HCV prevalence.
Last, we did not assess HCV genotype, a factor known to affect both
viral load and probability of natural clearance.33 Future genotype
assessment is planned and will provide important information for
treatment recommendations.
A high prevalence of HCV viremia has been detected among
IDUs previously exposed to HCV in three cities in Afghanistan. This
suggests ample opportunity for HCV transmission among IDUs
through shared injecting equipment and potentially to the
population at large through shared medical equipment. IDUs in
Afghanistan are vulnerable to this infection and efforts must be
focused on scaling up harm reduction programs to limit further
HCV transmission in this population. Currently, harm reduction
programs are being established or expanded in Hirat, Jalalabad and
Mazar-i-Sharif, indicating the feasibility of harm reduction
programs in Afghanistan, despite conservative culture, political
instability, and armed conﬂict. Encouragingly, the Kabul harm
reduction programs have established a harm reduction kit that is
provided to IDUs in the ﬁeld and includes sterile saline water
bottles, cotton gauze, and alcohol prep pads in addition to unused
syringes. We recommend that as voluntary HIV counseling and
testing is scaled up with harm reduction efforts, counseling and
testing for HCV and sterile injecting paraphernalia also be provided
to this vulnerable group to prevent further expansion of this
prevalent infection and associated morbidity and mortality.
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